Literature DB >> 31529718

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.

A Calugareanu1, M Jachiet1,2, M Tauber3, A Nosbaum4, F Aubin5, L Misery6, C Droitcourt7, S Barbarot8, S Debarbieux4, A Saussine1, M Bagot1,2, A de Masson1,2, J Sénéschal9, D Staumont-Sallé10, J-D Bouaziz1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31529718     DOI： 10.1111/jdv.15957

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  6 in total

1.  Pipeline Perspectives and Therapy Updates.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2020-11-01

2.  TRPV1 in Pain and Itch.

Authors:  Fengxian Li; Fang Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series.

Authors:  Louise Lönndahl; Maria Lundqvist; Maria Bradley; Emma K Johansson
Journal:  Acta Derm Venereol       Date:  2022-08-11       Impact factor: 3.875

Review 4.  Immunotargets and Therapy for Prurigo Nodularis.

Authors:  Angelina Labib; Teresa Ju; Ashley Vander Does; Gil Yosipovitch
Journal:  Immunotargets Ther       Date:  2022-04-26

Review 5.  Emerging Therapeutic Options for Chronic Pruritus.

Authors:  Radomir Reszke; Piotr Krajewski; Jacek C Szepietowski
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

Review 6.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.